{"entity":{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","aka":[],"tldr":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC.","summary":"Multiple myeloma is a cancer of antibody-producing plasma cells in the bone marrow, causing anaemia, bone destruction, kidney failure and infections. It is preceded by MGUS and smouldering myeloma, which are common (MGUS in ~3% of people over 50) and mostly harmless; whether to treat high-risk smouldering disease (AQUILA, daratumumab) is a live debate, and Iceland is screening its whole adult population (iStopMM). Staging (R-ISS/R2-ISS) and cytogenetics (del17p, t(4;14), 1q gain) drive prognosis; MRD negativity at one in a million marrow cells has become both the best prognostic marker and, since 2024, an accepted regulatory endpoint.\n\nNo cancer has gained more drug classes: proteasome inhibitors (bortezomib 2003, carfilzomib), immunomodulatory cereblon modulators (thalidomide, lenalidomide, pomalidomide; next-generation CELMoDs iberdomide and mezigdomide), CD38 antibodies (daratumumab, isatuximab), BCMA-directed CAR-T (ide-cel, cilta-cel; anito-cel decision December 2026), BCMA and GPRC5D bispecific T-cell engagers (teclistamab, elranatamab, linvoseltamab, talquetamab), a BCMA ADC (belantamab, withdrawn 2022 and re-approved 2025), plus XPO1 and BCL-2 inhibitors for subsets. Newly diagnosed patients receive a quadruplet (Dara-VRd or Isa-VRd) whether or not they proceed to autologous transplant (PERSEUS, CEPHEUS, IMROZ), then lenalidomide maintenance; median survival in fit patients now exceeds ten years. At relapse, cilta-cel (CARTITUDE-4, OS HR 0.55) and teclistamab plus daratumumab (MajesTEC-3, approved March 2026) are second-line options, with sequencing by prior antigen exposure.\n\nThe frontier is replacing transplant and indefinite maintenance with a single CAR-T infusion (CARTITUDE-5/6), MRD-guided stopping of therapy, trispecifics and combinations that pre-empt antigen escape, and CELMoDs that restore sensitivity after lenalidomide. The hard problems are high-risk cytogenetics and extramedullary disease, which respond briefly to everything; infections and prolonged cytopenias from T-cell redirection; delayed neurotoxicity after BCMA CAR-T; cost and manufacturing slots; and the fact that the disease still relapses in almost everyone eventually, so 'functional cure' remains a claim to be proven.","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Multiple_myeloma","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Multiple_myeloma"}],"tags":["heme","spike"],"related":["cd38-plus-triplet","bcma-then-gprc5d","bispecific-infection-prophylaxis","mmrf"],"cancers":[],"sections":[],"technologies":["car-t","t-cell-engager","adc","protac-degrader","whole-body-mri","mrd-testing","autologous-stem-cell-transplant","monoclonal-antibody","fdg-pet"],"targets":["bcma","gprc5d","cd38","cd3","tp53"],"drugs":["elotuzumab","panobinostat","sipuleucel-t","fluciclovine-f18","aminolevulinic-acid-gleolan","pegulicianine","clonoseq","carmustine","palifermin"],"companies":["nanjing-leads-biolabs","celltrion","chongqing-precision-biotech","shanghai-abelzeta","johnson-johnson","legend-biotech","bms","pfizer","regeneron","gsk","sanofi","amgen","takeda","gilead","genmab"],"institutions":["mskcc","dana-farber","mayo-clinic","md-anderson","mount-sinai"],"pathways":[],"terms":["r-iss","high-risk-myeloma","mrd-negativity-myeloma","smoldering-myeloma","mrd","crs","icans"],"trials":["nct07555938","nct07258511","nct07518186","nct07452198","nct07138209","quintessential-2","nct07297329","nct07579234","nct06508983","nct06868654","nct05730036","nct06952478","nct06464991","nct03844048","nct06956170","nct05438043","nct05572515","nct05623020","nct05827016","nct06152575","nct03539744","nct05519085","nct06514508","nct04975997","nct04162210","nct06413498","nct06158841","nct05020236","nct07095452","nct03246529","nct06208150","nct06679101","nct06868667","nct05552976","nct05317416","nct05552222","nct06045806","nct05455320","nct07393282","nct04270409","nct06980480","nct07742215"],"people":["maria-victoria-mateos","meletios-dimopoulos"],"bottlenecks":[],"keyPapers":[],"journals":["blood-cancer-discovery","blood-cancer-journal","clinical-lymphoma-myeloma-and-leukemia","current-hematologic-malignancy-reports","haematologica","journal-of-hematology-and-oncology"],"dependsOn":[],"notes":[],"group":"haematologic","burden":"Multiple myeloma causes ~190,000 new cases a year worldwide, ~36,000 in the US, at a median age of 69. More new drug classes than any other cancer have pushed median survival to more than 10 years in transplant-eligible patients and ~5-7 years in older patients; ~120,000 deaths a year worldwide.","subtypes":["Standard-risk vs high-risk cytogenetics (IMS 2024 definition)","Transplant-eligible vs transplant-ineligible (fitness, not age alone)","Extramedullary disease (soft-tissue plasmacytomas; harder to control, a focus of CAR-T and bispecific trials)","Plasma cell leukaemia (≥5% circulating plasma cells)","Light-chain only, IgA, IgG, non-secretory","Smouldering myeloma and MGUS (precursors)","Triple-class refractory / penta-refractory","BCMA-exposed vs BCMA-naive at relapse"],"biomarkers":["Cytogenetics (del17p, t(4;14), 1q gain)","R-ISS","MRD (NGS/flow)","BCMA/GPRC5D expression","Serum and urine M-protein, free light chains","R-ISS / R2-ISS (β2-microglobulin, albumin, LDH, FISH)","FISH: del(17p), t(4;14), t(14;16), t(14;20), 1q gain/amp, del(1p)","TP53 mutation","MRD by NGS (clonoSEQ) or next-generation flow at 10⁻⁵ to 10⁻⁶","PET-CT and whole-body MRI (IMWG imaging)","BCMA and GPRC5D expression / TNFRSF17 loss at relapse","Renal function, calcium, haemoglobin (CRAB criteria)","Soluble BCMA (research)"],"standardOfCare":[{"setting":"Newly diagnosed","approach":"Dara-VRd ± ASCT → lenalidomide maintenance.","refs":["whole-body-mri"],"guideline":{"version":"NCCN Guidelines: Multiple Myeloma","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1445"}},{"setting":"Relapsed","approach":"CAR-T or bispecific; belantamab combinations; sequencing by prior exposure.","refs":["ciltacabtagene-autoleucel","teclistamab","belantamab-mafodotin"],"guideline":{"version":"NCCN Guidelines: Multiple Myeloma","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1445"}},{"setting":"MGUS / low-risk smouldering","approach":"Observation with periodic labs; no treatment outside trials.","refs":["smoldering-myeloma","istopmm"],"guideline":{"nccn":"Observation","version":"NCCN Multiple Myeloma 2026"}},{"setting":"High-risk smouldering myeloma","approach":"Consider daratumumab monotherapy (AQUILA) or lenalidomide (E3A06), or trial enrolment; shared decision given indolent course in many.","refs":["daratumumab","lenalidomide","smoldering-myeloma"],"guideline":{"nccn":"Category 2A (daratumumab or lenalidomide for high-risk SMM)","version":"NCCN 2026"}},{"setting":"Newly diagnosed, transplant-eligible","approach":"Dara-VRd (or Isa-VRd) induction × 4-6 → stem-cell collection → high-dose melphalan + autologous transplant → Dara-VRd consolidation → lenalidomide (± daratumumab) maintenance; MRD-guided de-escalation emerging (PERSEUS design). Tandem transplant or extended therapy for high risk.","refs":["perseus","daratumumab","bortezomib","lenalidomide","autologous-stem-cell-transplant","mrd-negativity-myeloma"],"guideline":{"nccn":"Category 1 (Dara-VRd)","esmoMcbs":"A","version":"NCCN 2026 / EHA-ESMO 2021 update"}},{"setting":"Newly diagnosed, transplant-ineligible","approach":"Dara-VRd (CEPHEUS) or Isa-VRd (IMROZ) with bortezomib de-escalation after induction; Dara-Rd (MAIA) for frailer patients; continuous therapy with dose adjustment for frailty.","refs":["cepheus","imroz","daratumumab","isatuximab","lenalidomide"],"guideline":{"nccn":"Category 1","version":"NCCN 2026"}},{"setting":"Maintenance","approach":"Lenalidomide until progression (CALGB 100104, Myeloma XI); daratumumab added for high-risk or per PERSEUS; MRD-guided discontinuation in trials (DRAMMATIC, MASTER); iberdomide maintenance (EXCALIBER) pending.","refs":["lenalidomide","daratumumab","iberdomide","idea-mrd-guided-stop-myeloma","drammatic"]},{"setting":"First relapse (1-3 prior lines)","approach":"Cilta-cel if lenalidomide-refractory (CARTITUDE-4); teclistamab + daratumumab (MajesTEC-3, 2026); ide-cel after ≥2 lines; belantamab-Vd or -Pd (DREAMM-7/8); CD38-based triplets (Dara-Kd, Isa-Kd, Dara-Pd) by prior exposure; carfilzomib or pomalidomide combinations.","refs":["ciltacabtagene-autoleucel","cartitude-4","teclistamab","majestec-3","idecabtagene-vicleucel","karmma-3","belantamab-mafodotin","dreamm-7","dreamm-8","carfilzomib"],"guideline":{"nccn":"Category 1 (cilta-cel ≥1 line; tec-dara ≥1 line)","version":"NCCN 2026"}},{"setting":"Triple-class refractory (≥3-4 prior lines)","approach":"BCMA CAR-T if not yet given; bispecifics (teclistamab, elranatamab, linvoseltamab; talquetamab after BCMA exposure); belantamab; selinexor-based; CELMoDs in trials; anito-cel (PDUFA Dec 2026).","refs":["teclistamab","elranatamab","linvoseltamab","talquetamab","belantamab-mafodotin","mezigdomide","anitocabtagene-autoleucel","bcma-then-gprc5d"]},{"setting":"Supportive care","approach":"Bisphosphonate or denosumab for bone disease; IVIG, antiviral, PJP prophylaxis and vaccination during T-cell redirection; thromboprophylaxis with IMiDs; renal protection; radiotherapy for painful lesions or cord compression.","refs":["bispecific-infection-prophylaxis","imrt-igrt"]}],"stateOfArt":["CAR-T in second line.","Bispecifics after one prior line (2026).","Functional cure discussions.","Quadruplet induction (CD38 antibody + PI + IMiD + dexamethasone) for all newly diagnosed patients, with MRD negativity in 60-75%.","CAR-T with a survival benefit as early as second line (CARTITUDE-4, OS HR 0.55) and a third of late-line patients progression-free at five years without maintenance (CARTITUDE-1).","Two antigens for T-cell redirection (BCMA, GPRC5D) with four approved bispecifics; teclistamab plus daratumumab approved at first relapse (March 2026).","MRD negativity accepted by FDA as an endpoint for accelerated approval (2024), enabling faster trials and MRD-guided therapy.","Belantamab returned after withdrawal on the strength of two positive phase 3s, a rare regulatory reversal.","Nationwide precursor screening (iStopMM) and precursor treatment (AQUILA) are redefining where 'myeloma care' begins."],"history":[{"year":1844,"title":"First described case (Solly); Bence Jones protein 1847","refs":[]},{"year":1958,"title":"Melphalan introduced; melphalan-prednisone standard for 40 years","refs":["cytotoxic-chemotherapy"]},{"year":1983,"title":"High-dose melphalan with autologous marrow rescue (McElwain)","refs":["autologous-stem-cell-transplant"]},{"year":1996,"title":"IFM 90: transplant improves survival over chemotherapy","refs":["autologous-stem-cell-transplant"]},{"year":1999,"title":"Thalidomide shown active in refractory myeloma (Singhal, NEJM)","refs":[]},{"year":2003,"title":"Bortezomib approved","refs":[]},{"year":2003,"title":"Bortezomib: first proteasome inhibitor approved","refs":["bortezomib"]},{"year":2006,"title":"Lenalidomide approved","refs":["lenalidomide"]},{"year":2012,"title":"Carfilzomib approved; International Staging refined","refs":["carfilzomib"]},{"year":2015,"title":"Daratumumab approved","refs":[]},{"year":2015,"title":"Daratumumab: first CD38 antibody; R-ISS published","refs":["daratumumab","r-iss"]},{"year":2019,"title":"MAIA: Dara-Rd improves survival in transplant-ineligible disease","refs":["daratumumab"]},{"year":2020,"title":"Belantamab mafodotin: first BCMA ADC (accelerated; withdrawn 2022)","refs":["belantamab-mafodotin"]},{"year":2021,"title":"Ide-cel: first myeloma CAR-T","refs":[]},{"year":2021,"title":"Ide-cel: first myeloma CAR-T; CARTITUDE-1 shows 98% response","refs":["idecabtagene-vicleucel","cartitude-1"]},{"year":2022,"title":"Teclistamab: first myeloma bispecific","refs":["teclistamab"]},{"year":2022,"title":"Teclistamab: first myeloma bispecific; cilta-cel approved","refs":["teclistamab","majestec-1","ciltacabtagene-autoleucel"]},{"year":2023,"title":"CARTITUDE-4 and KarMMa-3 move CAR-T earlier; elranatamab and talquetamab approved","refs":["cartitude-4","karmma-3","elranatamab","talquetamab"]},{"year":2024,"title":"PERSEUS quadruplet approved; FDA accepts MRD as an endpoint; DREAMM-7/8 positive; cilta-cel and ide-cel approved after 1-2 lines","refs":["perseus","mrd-negativity-myeloma","dreamm-7","dreamm-8"]},{"year":2025,"title":"Linvoseltamab approved; belantamab re-approved; IMROZ/CEPHEUS labels; iMMagine-1 reports 97% ORR","refs":["linvoseltamab","linker-mm1","belantamab-mafodotin","imroz","cepheus","immagine-1"]},{"year":2026,"title":"Teclistamab after ≥1 line; isatuximab SC","refs":[]},{"year":2026,"title":"Teclistamab + daratumumab approved after ≥1 line (MajesTEC-3); isatuximab subcutaneous; anito-cel BLA accepted (PDUFA December)","refs":["majestec-3","isatuximab","anitocabtagene-autoleucel"]}],"pipeline":["teclistamab","ciltacabtagene-autoleucel","cevostamab","jnj-79635322","purinostat","gr1803","qls32015","arlocabtagene-autoleucel","sctc21c","f182112","sg301","gc012f","azd4045","sti-6129","feladilimab","anitocabtagene-autoleucel","immagine-1","cartitude-5","iberdomide","mezigdomide","talquetamab","linvoseltamab","elranatamab","istopmm","idea-mrd-guided-stop-myeloma","idea-car-t-replaces-transplant","bcma-then-gprc5d","mrd-negativity-myeloma","belantamab-mafodotin"],"openProblems":["High-risk cytogenetics.","Infections with T-cell redirecting therapy.","Cost and access.","High-risk cytogenetics and extramedullary disease respond briefly to every class; no regimen closes the gap.","Infections are the main safety problem on bispecifics; hypogammaglobulinaemia and T-cell exhaustion need better mitigation than IVIG and dose de-intensification.","Delayed neurotoxicity (parkinsonism, cranial neuropathies) after BCMA CAR-T and second primary malignancies after cereblon modulators and CAR-T.","Sequencing after BCMA failure: antigen loss (TNFRSF17 deletion) versus T-cell fitness; how to combine or alternate BCMA and GPRC5D agents.","Is transplant still needed? CARTITUDE-6 will answer; until then most fit patients receive high-dose melphalan.","Whether MRD-guided stopping is safe; whether MRD negativity at 10⁻⁶ equals cure for anyone.","Precursor disease: treating high-risk smouldering myeloma prevents progression but may over-treat; population screening's mortality effect is unknown.","Cost and capacity: CAR-T slots, bispecific hospitalisation for step-up dosing, and lifelong therapy costs strain every health system."],"prognosis":{"text":"In the United States, 63.7% of people diagnosed with myeloma in 2016-2022 were alive five years later, relative to people of the same age without the disease. Myeloma is a cancer of the bone marrow and is almost always systemic at diagnosis (96% of cases are recorded as distant), so stage-by-stage tables say little; risk is set instead by the Revised ISS, cytogenetics and fitness for transplant. The figures predate CAR-T and bispecific antibodies and are improving with each new line of treatment.","sources":[{"label":"SEER Cancer Stat Facts: Myeloma","url":"https://seer.cancer.gov/statfacts/html/mulmy.html"}]}},"route":"/cancers/multiple-myeloma/","neighbours":{"pairing":[{"id":"bcma-then-gprc5d","kind":"pairing","name":"BCMA-directed therapy → GPRC5D-directed therapy","route":"/pairings/bcma-then-gprc5d/"},{"id":"bispecific-infection-prophylaxis","kind":"pairing","name":"Caution: T-cell redirectors and infections","route":"/pairings/bispecific-infection-prophylaxis/"},{"id":"cd38-plus-triplet","kind":"pairing","name":"CD38 antibody added to PI-IMiD-dex (quadruplet induction)","route":"/pairings/cd38-plus-triplet/"}],"collection":[{"id":"leukemia-lymphoma-society","kind":"collection","name":"Leukemia & Lymphoma Society (LLS)","route":"/collections/leukemia-lymphoma-society/"},{"id":"mmrf","kind":"collection","name":"Multiple Myeloma Research Foundation (MMRF)","route":"/collections/mmrf/"}],"technology":[{"id":"allogeneic-cell-banks","kind":"technology","name":"Allogeneic cell banks: one donor, hundreds of doses","route":"/technologies/allogeneic-cell-banks/"},{"id":"allogeneic-hsct","kind":"technology","name":"Allogeneic stem cell transplantation","route":"/technologies/allogeneic-hsct/"},{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"car-t-manufacturing-process","kind":"technology","name":"Autologous CAR-T manufacturing, batch by batch","route":"/technologies/car-t-manufacturing-process/"},{"id":"autologous-stem-cell-transplant","kind":"technology","name":"Autologous stem cell transplant (high-dose therapy)","route":"/technologies/autologous-stem-cell-transplant/"},{"id":"rejuv-rehab-balance-vestibular","kind":"technology","name":"Balance, dizziness and falls after cancer treatment","route":"/technologies/rejuv-rehab-balance-vestibular/"},{"id":"cancer-treatment-bone-loss","kind":"technology","name":"Bone loss caused by cancer treatment, and what rebuilds it","route":"/technologies/cancer-treatment-bone-loss/"},{"id":"bone-modifying-agents","kind":"technology","name":"Bone-modifying agents (bisphosphonates, denosumab)","route":"/technologies/bone-modifying-agents/"},{"id":"cancer-associated-thrombosis","kind":"technology","name":"Cancer-associated thrombosis prevention and treatment","route":"/technologies/cancer-associated-thrombosis/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"celmods","kind":"technology","name":"Cereblon E3 ligase modulators (CELMoDs)","route":"/technologies/celmods/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"dual-energy-spectral-ct","kind":"technology","name":"Dual-energy and spectral CT","route":"/technologies/dual-energy-spectral-ct/"},{"id":"rejuv-life-employment-rights-us","kind":"technology","name":"Employment rights with cancer in the United States","route":"/technologies/rejuv-life-employment-rights-us/"},{"id":"functional-precision-medicine-haematology","kind":"technology","name":"Ex vivo drug sensitivity screening in blood cancers (EXALT)","route":"/technologies/functional-precision-medicine-haematology/"},{"id":"rejuv-access-exercise-programmes","kind":"technology","name":"Exercise is the best-evidenced thing on this front, and most survivors are not doing it","route":"/technologies/rejuv-access-exercise-programmes/"},{"id":"rejuv-measure-fact-and-facit","kind":"technology","name":"FACT-G and the FACIT family: the other main questionnaire","route":"/technologies/rejuv-measure-fact-and-facit/"},{"id":"fdg-pet","kind":"technology","name":"FDG PET","route":"/technologies/fdg-pet/"},{"id":"flow-cytometers","kind":"technology","name":"Flow cytometers","route":"/technologies/flow-cytometers/"},{"id":"gamma-secretase-inhibitors","kind":"technology","name":"Gamma-secretase inhibitors","route":"/technologies/gamma-secretase-inhibitors/"},{"id":"rejuv-measure-patient-reported-outcomes","kind":"technology","name":"How recovery is measured: the questionnaires behind the numbers","route":"/technologies/rejuv-measure-patient-reported-outcomes/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"rejuv-life-money-after-treatment","kind":"technology","name":"Money after treatment: what the cost of cancer does once the treatment has finished","route":"/technologies/rejuv-life-money-after-treatment/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"mri-field-strengths","kind":"technology","name":"MRI field strengths: 1.5 T, 3 T and 7 T","route":"/technologies/mri-field-strengths/"},{"id":"flow-cytometry-mrd","kind":"technology","name":"Multiparameter flow cytometry MRD","route":"/technologies/flow-cytometry-mrd/"},{"id":"cipn-recovery-and-treatment","kind":"technology","name":"Nerve damage from chemotherapy: what recovers, and what helps","route":"/technologies/cipn-recovery-and-treatment/"},{"id":"ngs-mrd-clonoseq","kind":"technology","name":"NGS-based MRD (clonoSEQ and molecular MRD)","route":"/technologies/ngs-mrd-clonoseq/"},{"id":"oncolytic-virus","kind":"technology","name":"Oncolytic viruses","route":"/technologies/oncolytic-virus/"},{"id":"palliative-radiotherapy","kind":"technology","name":"Palliative radiotherapy","route":"/technologies/palliative-radiotherapy/"},{"id":"photobiomodulation-mucositis","kind":"technology","name":"Photobiomodulation (low-level laser) for oral mucositis","route":"/technologies/photobiomodulation-mucositis/"},{"id":"photon-counting-ct","kind":"technology","name":"Photon-counting CT","route":"/technologies/photon-counting-ct/"},{"id":"rejuv-measure-pro-ctcae","kind":"technology","name":"PRO-CTCAE: side effects graded by the person having them","route":"/technologies/rejuv-measure-pro-ctcae/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"},{"id":"scrambler-therapy","kind":"technology","name":"Scrambler therapy (Calmare) for chemotherapy nerve pain","route":"/technologies/scrambler-therapy/"},{"id":"serum-tumour-markers","kind":"technology","name":"Serum tumour markers: proper use and misuse","route":"/technologies/serum-tumour-markers/"},{"id":"rejuv-mind-sleeping-tablets-after-cancer","kind":"technology","name":"Sleeping tablets after cancer: what they do and what they do not","route":"/technologies/rejuv-mind-sleeping-tablets-after-cancer/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"},{"id":"trispecific-antibodies","kind":"technology","name":"Trispecific antibodies","route":"/technologies/trispecific-antibodies/"},{"id":"rejuv-measure-functional-tests","kind":"technology","name":"Walking, gripping and standing up: the tests that take five minutes","route":"/technologies/rejuv-measure-functional-tests/"},{"id":"rejuv-measure-wearables-and-step-counts","kind":"technology","name":"Wearables and step counts: measuring what someone actually does","route":"/technologies/rejuv-measure-wearables-and-step-counts/"},{"id":"rejuv-access-what-it-costs-us","kind":"technology","name":"What recovery costs in the United States","route":"/technologies/rejuv-access-what-it-costs-us/"},{"id":"rejuv-rehab-commissioning-inequity","kind":"technology","name":"Where rehabilitation is commissioned, and who misses out","route":"/technologies/rejuv-rehab-commissioning-inequity/"},{"id":"whole-body-mri","kind":"technology","name":"Whole-body MRI","route":"/technologies/whole-body-mri/"},{"id":"x-ray-radiography-fluoroscopy","kind":"technology","name":"X-ray radiography and fluoroscopy","route":"/technologies/x-ray-radiography-fluoroscopy/"}],"target":[{"id":"adamts9","kind":"target","name":"ADAMTS9","route":"/targets/adamts9/"},{"id":"adrm1","kind":"target","name":"ADRM1","route":"/targets/adrm1/"},{"id":"arhgap5","kind":"target","name":"ARHGAP5","route":"/targets/arhgap5/"},{"id":"bcl7a","kind":"target","name":"BCL7A","route":"/targets/bcl7a/"},{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"},{"id":"btg1","kind":"target","name":"BTG1","route":"/targets/btg1/"},{"id":"ccnd1","kind":"target","name":"CCND1","route":"/targets/ccnd1/"},{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"},{"id":"cd38","kind":"target","name":"CD38","route":"/targets/cd38/"},{"id":"cd3d","kind":"target","name":"CD3D","route":"/targets/cd3d/"},{"id":"cd3g","kind":"target","name":"CD3G","route":"/targets/cd3g/"},{"id":"cdkn1b","kind":"target","name":"CDKN1B","route":"/targets/cdkn1b/"},{"id":"cereblon","kind":"target","name":"Cereblon (CRBN)","route":"/targets/cereblon/"},{"id":"col1a1","kind":"target","name":"COL1A1","route":"/targets/col1a1/"},{"id":"ctag1b","kind":"target","name":"CTAG1B","route":"/targets/ctag1b/"},{"id":"ctag2","kind":"target","name":"CTAG2","route":"/targets/ctag2/"},{"id":"cul4a","kind":"target","name":"CUL4A","route":"/targets/cul4a/"},{"id":"cxcr4","kind":"target","name":"CXCR4","route":"/targets/cxcr4/"},{"id":"cyld","kind":"target","name":"CYLD","route":"/targets/cyld/"},{"id":"ddb1","kind":"target","name":"DDB1","route":"/targets/ddb1/"},{"id":"dis3","kind":"target","name":"DIS3","route":"/targets/dis3/"},{"id":"eftud2","kind":"target","name":"EFTUD2","route":"/targets/eftud2/"},{"id":"xpo1","kind":"target","name":"Exportin-1 (XPO1)","route":"/targets/xpo1/"},{"id":"fcrh5","kind":"target","name":"FcRH5 (FCRL5)","route":"/targets/fcrh5/"},{"id":"fdps","kind":"target","name":"FDPS","route":"/targets/fdps/"},{"id":"glucocorticoid-receptor","kind":"target","name":"Glucocorticoid receptor (NR3C1)","route":"/targets/glucocorticoid-receptor/"},{"id":"gprc5d","kind":"target","name":"GPRC5D","route":"/targets/gprc5d/"},{"id":"hdac10","kind":"target","name":"HDAC10","route":"/targets/hdac10/"},{"id":"hdac11","kind":"target","name":"HDAC11","route":"/targets/hdac11/"},{"id":"hdac4","kind":"target","name":"HDAC4","route":"/targets/hdac4/"},{"id":"hdac5","kind":"target","name":"HDAC5","route":"/targets/hdac5/"},{"id":"hdac7","kind":"target","name":"HDAC7","route":"/targets/hdac7/"},{"id":"hdac8","kind":"target","name":"HDAC8","route":"/targets/hdac8/"},{"id":"hdac9","kind":"target","name":"HDAC9","route":"/targets/hdac9/"},{"id":"hdac","kind":"target","name":"Histone deacetylases (HDAC)","route":"/targets/hdac/"},{"id":"ifnar2","kind":"target","name":"IFNAR2","route":"/targets/ifnar2/"},{"id":"ikbkb","kind":"target","name":"IKBKB","route":"/targets/ikbkb/"},{"id":"ikzf1","kind":"target","name":"IKZF1 (Ikaros)","route":"/targets/ikzf1/"},{"id":"ikzf3","kind":"target","name":"IKZF3 (Aiolos)","route":"/targets/ikzf3/"},{"id":"il6","kind":"target","name":"Interleukin-6 and IL-6 receptor","route":"/targets/il6/"},{"id":"irak1","kind":"target","name":"IRAK1","route":"/targets/irak1/"},{"id":"irf1","kind":"target","name":"IRF1","route":"/targets/irf1/"},{"id":"irf4","kind":"target","name":"IRF4","route":"/targets/irf4/"},{"id":"kdm5c","kind":"target","name":"KDM5C","route":"/targets/kdm5c/"},{"id":"maf","kind":"target","name":"MAF","route":"/targets/maf/"},{"id":"max","kind":"target","name":"MAX","route":"/targets/max/"},{"id":"mcl1","kind":"target","name":"MCL1","route":"/targets/mcl1/"},{"id":"myc-gene","kind":"target","name":"MYC","route":"/targets/myc-gene/"},{"id":"mycl","kind":"target","name":"MYCL","route":"/targets/mycl/"},{"id":"nfkbia","kind":"target","name":"NFKBIA","route":"/targets/nfkbia/"},{"id":"nsd2","kind":"target","name":"NSD2","route":"/targets/nsd2/"},{"id":"pabpc1","kind":"target","name":"PABPC1","route":"/targets/pabpc1/"},{"id":"parp4","kind":"target","name":"PARP4","route":"/targets/parp4/"},{"id":"pim1","kind":"target","name":"PIM1","route":"/targets/pim1/"},{"id":"prdm1","kind":"target","name":"PRDM1","route":"/targets/prdm1/"},{"id":"prdm16","kind":"target","name":"PRDM16","route":"/targets/prdm16/"},{"id":"prkd2","kind":"target","name":"PRKD2","route":"/targets/prkd2/"},{"id":"proteasome","kind":"target","name":"Proteasome (PSMB5)","route":"/targets/proteasome/"},{"id":"psma1","kind":"target","name":"PSMA1","route":"/targets/psma1/"},{"id":"psma2","kind":"target","name":"PSMA2","route":"/targets/psma2/"},{"id":"psma3","kind":"target","name":"PSMA3","route":"/targets/psma3/"},{"id":"psma4","kind":"target","name":"PSMA4","route":"/targets/psma4/"},{"id":"psma5","kind":"target","name":"PSMA5","route":"/targets/psma5/"},{"id":"psma6","kind":"target","name":"PSMA6","route":"/targets/psma6/"},{"id":"psma7","kind":"target","name":"PSMA7","route":"/targets/psma7/"},{"id":"psma8","kind":"target","name":"PSMA8","route":"/targets/psma8/"},{"id":"psmb1","kind":"target","name":"PSMB1","route":"/targets/psmb1/"},{"id":"psmb10","kind":"target","name":"PSMB10","route":"/targets/psmb10/"},{"id":"psmb11","kind":"target","name":"PSMB11","route":"/targets/psmb11/"},{"id":"psmb2","kind":"target","name":"PSMB2","route":"/targets/psmb2/"},{"id":"psmb3","kind":"target","name":"PSMB3","route":"/targets/psmb3/"},{"id":"psmb4","kind":"target","name":"PSMB4","route":"/targets/psmb4/"},{"id":"psmb6","kind":"target","name":"PSMB6","route":"/targets/psmb6/"},{"id":"psmb7","kind":"target","name":"PSMB7","route":"/targets/psmb7/"},{"id":"psmb8","kind":"target","name":"PSMB8","route":"/targets/psmb8/"},{"id":"psmb9","kind":"target","name":"PSMB9","route":"/targets/psmb9/"},{"id":"psmc1","kind":"target","name":"PSMC1","route":"/targets/psmc1/"},{"id":"psmc2","kind":"target","name":"PSMC2","route":"/targets/psmc2/"},{"id":"psmc3","kind":"target","name":"PSMC3","route":"/targets/psmc3/"},{"id":"psmc4","kind":"target","name":"PSMC4","route":"/targets/psmc4/"},{"id":"psmc5","kind":"target","name":"PSMC5","route":"/targets/psmc5/"},{"id":"psmc6","kind":"target","name":"PSMC6","route":"/targets/psmc6/"},{"id":"psmd1","kind":"target","name":"PSMD1","route":"/targets/psmd1/"},{"id":"psmd11","kind":"target","name":"PSMD11","route":"/targets/psmd11/"},{"id":"psmd12","kind":"target","name":"PSMD12","route":"/targets/psmd12/"},{"id":"psmd13","kind":"target","name":"PSMD13","route":"/targets/psmd13/"},{"id":"psmd14","kind":"target","name":"PSMD14","route":"/targets/psmd14/"},{"id":"psmd2","kind":"target","name":"PSMD2","route":"/targets/psmd2/"},{"id":"psmd3","kind":"target","name":"PSMD3","route":"/targets/psmd3/"},{"id":"psmd4","kind":"target","name":"PSMD4","route":"/targets/psmd4/"},{"id":"psmd6","kind":"target","name":"PSMD6","route":"/targets/psmd6/"},{"id":"psmd7","kind":"target","name":"PSMD7","route":"/targets/psmd7/"},{"id":"psmd8","kind":"target","name":"PSMD8","route":"/targets/psmd8/"},{"id":"rankl","kind":"target","name":"RANK ligand (RANKL)","route":"/targets/rankl/"},{"id":"rbx1","kind":"target","name":"RBX1","route":"/targets/rbx1/"},{"id":"rpl10","kind":"target","name":"RPL10","route":"/targets/rpl10/"},{"id":"rps3a","kind":"target","name":"RPS3A","route":"/targets/rps3a/"},{"id":"samhd1","kind":"target","name":"SAMHD1","route":"/targets/samhd1/"},{"id":"sem1","kind":"target","name":"SEM1","route":"/targets/sem1/"},{"id":"slamf7","kind":"target","name":"SLAMF7 (CS1)","route":"/targets/slamf7/"},{"id":"sp140","kind":"target","name":"SP140","route":"/targets/sp140/"},{"id":"tent5c","kind":"target","name":"TENT5C","route":"/targets/tent5c/"},{"id":"tnfrsf13b","kind":"target","name":"TNFRSF13B","route":"/targets/tnfrsf13b/"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/"},{"id":"traf3","kind":"target","name":"TRAF3","route":"/targets/traf3/"},{"id":"tuba1a","kind":"target","name":"TUBA1A","route":"/targets/tuba1a/"},{"id":"tuba1b","kind":"target","name":"TUBA1B","route":"/targets/tuba1b/"},{"id":"tuba1c","kind":"target","name":"TUBA1C","route":"/targets/tuba1c/"},{"id":"tuba3c","kind":"target","name":"TUBA3C","route":"/targets/tuba3c/"},{"id":"tuba3e","kind":"target","name":"TUBA3E","route":"/targets/tuba3e/"},{"id":"tuba4a","kind":"target","name":"TUBA4A","route":"/targets/tuba4a/"},{"id":"tubb1","kind":"target","name":"TUBB1","route":"/targets/tubb1/"},{"id":"tubb2a","kind":"target","name":"TUBB2A","route":"/targets/tubb2a/"},{"id":"tubb2b","kind":"target","name":"TUBB2B","route":"/targets/tubb2b/"},{"id":"tubb3","kind":"target","name":"TUBB3","route":"/targets/tubb3/"},{"id":"tubb4a","kind":"target","name":"TUBB4A","route":"/targets/tubb4a/"},{"id":"tubb4b","kind":"target","name":"TUBB4B","route":"/targets/tubb4b/"},{"id":"tubb6","kind":"target","name":"TUBB6","route":"/targets/tubb6/"},{"id":"tubb8","kind":"target","name":"TUBB8","route":"/targets/tubb8/"},{"id":"usp7","kind":"target","name":"USP7","route":"/targets/usp7/"},{"id":"usp8","kind":"target","name":"USP8","route":"/targets/usp8/"},{"id":"zeb1","kind":"target","name":"ZEB1","route":"/targets/zeb1/"},{"id":"zfhx3","kind":"target","name":"ZFHX3","route":"/targets/zfhx3/"}],"drug":[{"id":"aminolevulinic-acid-gleolan","kind":"drug","name":"5-Aminolevulinic acid (oral, for glioma surgery)","route":"/drugs/aminolevulinic-acid-gleolan/"},{"id":"anitocabtagene-autoleucel","kind":"drug","name":"Anitocabtagene autoleucel","route":"/drugs/anitocabtagene-autoleucel/"},{"id":"arlocabtagene-autoleucel","kind":"drug","name":"Arlocabtagene Autoleucel","route":"/drugs/arlocabtagene-autoleucel/"},{"id":"azd0120","kind":"drug","name":"AZD0120","route":"/drugs/azd0120/"},{"id":"azd4045","kind":"drug","name":"AZD4045","route":"/drugs/azd4045/"},{"id":"belantamab-mafodotin","kind":"drug","name":"Belantamab mafodotin","route":"/drugs/belantamab-mafodotin/"},{"id":"bortezomib","kind":"drug","name":"Bortezomib","route":"/drugs/bortezomib/"},{"id":"carfilzomib","kind":"drug","name":"Carfilzomib","route":"/drugs/carfilzomib/"},{"id":"carmustine","kind":"drug","name":"Carmustine","route":"/drugs/carmustine/"},{"id":"cevostamab","kind":"drug","name":"Cevostamab","route":"/drugs/cevostamab/"},{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/"},{"id":"clonoseq","kind":"drug","name":"clonoSEQ","route":"/drugs/clonoseq/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/"},{"id":"denosumab","kind":"drug","name":"Denosumab","route":"/drugs/denosumab/"},{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"},{"id":"elotuzumab","kind":"drug","name":"Elotuzumab","route":"/drugs/elotuzumab/"},{"id":"elranatamab","kind":"drug","name":"Elranatamab","route":"/drugs/elranatamab/"},{"id":"equecabtagene-autoleucel","kind":"drug","name":"Equecabtagene autoleucel","route":"/drugs/equecabtagene-autoleucel/"},{"id":"f182112","kind":"drug","name":"F182112","route":"/drugs/f182112/"},{"id":"feladilimab","kind":"drug","name":"Feladilimab","route":"/drugs/feladilimab/"},{"id":"fluciclovine-f18","kind":"drug","name":"Fluciclovine F-18","route":"/drugs/fluciclovine-f18/"},{"id":"gc012f","kind":"drug","name":"GC012F","route":"/drugs/gc012f/"},{"id":"gr1803","kind":"drug","name":"GR1803","route":"/drugs/gr1803/"},{"id":"human-normal-immunoglobulin","kind":"drug","name":"Human normal immunoglobulin (IVIg)","route":"/drugs/human-normal-immunoglobulin/"},{"id":"iberdomide","kind":"drug","name":"Iberdomide","route":"/drugs/iberdomide/"},{"id":"idecabtagene-vicleucel","kind":"drug","name":"Idecabtagene vicleucel","route":"/drugs/idecabtagene-vicleucel/"},{"id":"isatuximab","kind":"drug","name":"Isatuximab","route":"/drugs/isatuximab/"},{"id":"isb-2001","kind":"drug","name":"ISB 2001","route":"/drugs/isb-2001/"},{"id":"ixazomib","kind":"drug","name":"Ixazomib","route":"/drugs/ixazomib/"},{"id":"jnj-79635322","kind":"drug","name":"JNJ-79635322","route":"/drugs/jnj-79635322/"},{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"},{"id":"linvoseltamab","kind":"drug","name":"Linvoseltamab","route":"/drugs/linvoseltamab/"},{"id":"melphalan","kind":"drug","name":"Melphalan (including hepatic delivery system)","route":"/drugs/melphalan/"},{"id":"melflufen","kind":"drug","name":"Melphalan flufenamide","route":"/drugs/melflufen/"},{"id":"mezigdomide","kind":"drug","name":"Mezigdomide","route":"/drugs/mezigdomide/"},{"id":"motixafortide","kind":"drug","name":"Motixafortide","route":"/drugs/motixafortide/"},{"id":"nxc-201-car-t","kind":"drug","name":"NXC-201 CAR-T","route":"/drugs/nxc-201-car-t/"},{"id":"palifermin","kind":"drug","name":"Palifermin","route":"/drugs/palifermin/"},{"id":"pamidronate","kind":"drug","name":"Pamidronate","route":"/drugs/pamidronate/"},{"id":"panobinostat","kind":"drug","name":"Panobinostat","route":"/drugs/panobinostat/"},{"id":"pegulicianine","kind":"drug","name":"Pegulicianine","route":"/drugs/pegulicianine/"},{"id":"pegylated-liposomal-doxorubicin","kind":"drug","name":"Pegylated liposomal doxorubicin","route":"/drugs/pegylated-liposomal-doxorubicin/"},{"id":"plerixafor","kind":"drug","name":"Plerixafor","route":"/drugs/plerixafor/"},{"id":"plitidepsin","kind":"drug","name":"Plitidepsin","route":"/drugs/plitidepsin/"},{"id":"pomalidomide","kind":"drug","name":"Pomalidomide","route":"/drugs/pomalidomide/"},{"id":"purinostat","kind":"drug","name":"Purinostat","route":"/drugs/purinostat/"},{"id":"qls32015","kind":"drug","name":"QLS32015","route":"/drugs/qls32015/"},{"id":"sctc21c","kind":"drug","name":"SCTC21C","route":"/drugs/sctc21c/"},{"id":"selinexor","kind":"drug","name":"Selinexor","route":"/drugs/selinexor/"},{"id":"sg301","kind":"drug","name":"SG301","route":"/drugs/sg301/"},{"id":"sipuleucel-t","kind":"drug","name":"Sipuleucel-T","route":"/drugs/sipuleucel-t/"},{"id":"sti-6129","kind":"drug","name":"STI-6129","route":"/drugs/sti-6129/"},{"id":"talquetamab","kind":"drug","name":"Talquetamab","route":"/drugs/talquetamab/"},{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/"},{"id":"thalidomide","kind":"drug","name":"Thalidomide","route":"/drugs/thalidomide/"},{"id":"zevorcabtagene-autoleucel","kind":"drug","name":"Zevorcabtagene autoleucel","route":"/drugs/zevorcabtagene-autoleucel/"},{"id":"zoledronic-acid","kind":"drug","name":"Zoledronic acid","route":"/drugs/zoledronic-acid/"}],"company":[{"id":"active-biotech","kind":"company","name":"Active Biotech","route":"/companies/active-biotech/"},{"id":"adaptive-biotechnologies","kind":"company","name":"Adaptive Biotechnologies","route":"/companies/adaptive-biotechnologies/"},{"id":"aeterna-zentaris","kind":"company","name":"Aeterna Zentaris","route":"/companies/aeterna-zentaris/"},{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"},{"id":"angiocrine-bioscience","kind":"company","name":"Angiocrine Bioscience","route":"/companies/angiocrine-bioscience/"},{"id":"antengene","kind":"company","name":"Antengene","route":"/companies/antengene/"},{"id":"arcellx","kind":"company","name":"Arcellx","route":"/companies/arcellx/"},{"id":"aurigene","kind":"company","name":"Aurigene Oncology","route":"/companies/aurigene/"},{"id":"biolinerx","kind":"company","name":"BioLineRx","route":"/companies/biolinerx/"},{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"},{"id":"c4-therapeutics","kind":"company","name":"C4 Therapeutics","route":"/companies/c4-therapeutics/"},{"id":"cartesian-therapeutics","kind":"company","name":"Cartesian Therapeutics","route":"/companies/cartesian-therapeutics/"},{"id":"cellectar","kind":"company","name":"Cellectar Biosciences","route":"/companies/cellectar/"},{"id":"celltrion","kind":"company","name":"Celltrion","route":"/companies/celltrion/"},{"id":"chongqing-precision-biotech","kind":"company","name":"Chongqing Precision Biotech","route":"/companies/chongqing-precision-biotech/"},{"id":"european-myeloma-network","kind":"company","name":"European Myeloma Network","route":"/companies/european-myeloma-network/"},{"id":"foghorn-therapeutics","kind":"company","name":"Foghorn Therapeutics","route":"/companies/foghorn-therapeutics/"},{"id":"genmab","kind":"company","name":"Genmab","route":"/companies/genmab/"},{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/"},{"id":"gimema","kind":"company","name":"GIMEMA","route":"/companies/gimema/"},{"id":"glenmark","kind":"company","name":"Glenmark Pharmaceuticals (Ichnos Glenmark Innovation)","route":"/companies/glenmark/"},{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"},{"id":"hangzhou-sumgen-biotech","kind":"company","name":"Hangzhou Sumgen Biotech","route":"/companies/hangzhou-sumgen-biotech/"},{"id":"heidelberg-pharma","kind":"company","name":"Heidelberg Pharma","route":"/companies/heidelberg-pharma/"},{"id":"hovon","kind":"company","name":"HOVON","route":"/companies/hovon/"},{"id":"indapta-therapeutics","kind":"company","name":"Indapta Therapeutics","route":"/companies/indapta-therapeutics/"},{"id":"ifm","kind":"company","name":"Intergroupe Francophone du Myélome (IFM)","route":"/companies/ifm/"},{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"},{"id":"jw-pharmaceutical","kind":"company","name":"JW Pharmaceutical","route":"/companies/jw-pharmaceutical/"},{"id":"k36-therapeutics","kind":"company","name":"K36 Therapeutics","route":"/companies/k36-therapeutics/"},{"id":"kelonia-therapeutics","kind":"company","name":"Kelonia Therapeutics","route":"/companies/kelonia-therapeutics/"},{"id":"legend-biotech","kind":"company","name":"Legend Biotech","route":"/companies/legend-biotech/"},{"id":"lls-therapy-acceleration-program","kind":"company","name":"Leukemia & Lymphoma Society Therapy Acceleration Program","route":"/companies/lls-therapy-acceleration-program/"},{"id":"mission-bio","kind":"company","name":"Mission Bio","route":"/companies/mission-bio/"},{"id":"mmrf-myeloma-investment-fund","kind":"company","name":"Multiple Myeloma Research Foundation and Myeloma Investment Fund","route":"/companies/mmrf-myeloma-investment-fund/"},{"id":"nanjing-leads-biolabs","kind":"company","name":"Nanjing Leads Biolabs","route":"/companies/nanjing-leads-biolabs/"},{"id":"oncopeptides","kind":"company","name":"Oncopeptides","route":"/companies/oncopeptides/"},{"id":"orna-therapeutics","kind":"company","name":"Orna Therapeutics (Eli Lilly)","route":"/companies/orna-therapeutics/"},{"id":"outcomes4me","kind":"company","name":"Outcomes4Me","route":"/companies/outcomes4me/"},{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"},{"id":"poseida-therapeutics","kind":"company","name":"Poseida Therapeutics","route":"/companies/poseida-therapeutics/"},{"id":"qilu-pharmaceutical","kind":"company","name":"Qilu Pharmaceutical","route":"/companies/qilu-pharmaceutical/"},{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/"},{"id":"sanofi","kind":"company","name":"Sanofi","route":"/companies/sanofi/"},{"id":"shanghai-abelzeta","kind":"company","name":"Shanghai AbelZeta","route":"/companies/shanghai-abelzeta/"},{"id":"sinocelltech","kind":"company","name":"Sinocelltech","route":"/companies/sinocelltech/"},{"id":"sonalasense","kind":"company","name":"SonALAsense","route":"/companies/sonalasense/"},{"id":"sorrento-therapeutics","kind":"company","name":"Sorrento Therapeutics","route":"/companies/sorrento-therapeutics/"},{"id":"takeda","kind":"company","name":"Takeda","route":"/companies/takeda/"}],"institution":[{"id":"ash","kind":"institution","name":"American Society of Hematology","route":"/institutions/ash/"},{"id":"blood-cancer-uk","kind":"institution","name":"Blood Cancer UK","route":"/institutions/blood-cancer-uk/"},{"id":"cun-navarra","kind":"institution","name":"Cancer Center Clínica Universidad de Navarra / CIMA","route":"/institutions/cun-navarra/"},{"id":"aphp-nord-cancer-institute","kind":"institution","name":"Cancer Institute AP-HP Nord, Université Paris Cité","route":"/institutions/aphp-nord-cancer-institute/"},{"id":"cmc-vellore","kind":"institution","name":"Christian Medical College, Vellore","route":"/institutions/cmc-vellore/"},{"id":"ccc-wuerzburg","kind":"institution","name":"Comprehensive Cancer Center Mainfranken, University Hospital Würzburg","route":"/institutions/ccc-wuerzburg/"},{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/"},{"id":"eha","kind":"institution","name":"European Hematology Association","route":"/institutions/eha/"},{"id":"hadassah","kind":"institution","name":"Hadassah Medical Center","route":"/institutions/hadassah/"},{"id":"hospital-clinic-barcelona","kind":"institution","name":"Hospital Clínic de Barcelona / IDIBAPS","route":"/institutions/hospital-clinic-barcelona/"},{"id":"12-de-octubre","kind":"institution","name":"Hospital Universitario 12 de Octubre","route":"/institutions/12-de-octubre/"},{"id":"sant-orsola-bologna","kind":"institution","name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola","route":"/institutions/sant-orsola-bologna/"},{"id":"iuct-oncopole","kind":"institution","name":"IUCT Oncopole (Institut Universitaire du Cancer de Toulouse)","route":"/institutions/iuct-oncopole/"},{"id":"leeds-cancer-centre","kind":"institution","name":"Leeds Cancer Centre, St James's University Hospital","route":"/institutions/leeds-cancer-centre/"},{"id":"chu-lille","kind":"institution","name":"Lille University Hospital (CHU de Lille)","route":"/institutions/chu-lille/"},{"id":"mayo-clinic","kind":"institution","name":"Mayo Clinic","route":"/institutions/mayo-clinic/"},{"id":"mayo-clinic-arizona","kind":"institution","name":"Mayo Clinic Comprehensive Cancer Center in Arizona","route":"/institutions/mayo-clinic-arizona/"},{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"},{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"},{"id":"chu-nantes","kind":"institution","name":"Nantes University Hospital (CHU de Nantes)","route":"/institutions/chu-nantes/"},{"id":"nkua-athens","kind":"institution","name":"National and Kapodistrian University of Athens, School of Medicine","route":"/institutions/nkua-athens/"},{"id":"rambam","kind":"institution","name":"Rambam Health Care Campus","route":"/institutions/rambam/"},{"id":"seoul-st-marys-hospital","kind":"institution","name":"Seoul St. Mary's Hospital","route":"/institutions/seoul-st-marys-hospital/"},{"id":"sylvester-miami","kind":"institution","name":"Sylvester Comprehensive Cancer Center, University of Miami","route":"/institutions/sylvester-miami/"},{"id":"technion","kind":"institution","name":"Technion, Israel Institute of Technology","route":"/institutions/technion/"},{"id":"tennessee-oncology","kind":"institution","name":"Tennessee Oncology / Greco-Hainsworth Centers for Research","route":"/institutions/tennessee-oncology/"},{"id":"mount-sinai","kind":"institution","name":"The Mount Sinai Hospital / Tisch Cancer Institute","route":"/institutions/mount-sinai/"},{"id":"ku-cancer-center","kind":"institution","name":"The University of Kansas Cancer Center","route":"/institutions/ku-cancer-center/"},{"id":"union-hospital-wuhan","kind":"institution","name":"Union Hospital, Tongji Medical College","route":"/institutions/union-hospital-wuhan/"},{"id":"hospital-universitario-salamanca","kind":"institution","name":"University Hospital of Salamanca / IBSAL","route":"/institutions/hospital-universitario-salamanca/"},{"id":"maryland-greenebaum","kind":"institution","name":"University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center","route":"/institutions/maryland-greenebaum/"},{"id":"vcu-massey","kind":"institution","name":"VCU Massey Comprehensive Cancer Center","route":"/institutions/vcu-massey/"},{"id":"emory-winship","kind":"institution","name":"Winship Cancer Institute of Emory University","route":"/institutions/emory-winship/"}],"term":[{"id":"rejuv-second-alkylating-agents-and-myeloid-neoplasms","kind":"term","name":"Alkylating agents and therapy-related myeloid neoplasms","route":"/terms/rejuv-second-alkylating-agents-and-myeloid-neoplasms/"},{"id":"autologous-transplant","kind":"term","name":"Autologous stem cell transplant (ASCT)","route":"/terms/autologous-transplant/"},{"id":"b-cell","kind":"term","name":"B cell","route":"/terms/b-cell/"},{"id":"bone-metastases","kind":"term","name":"Bone metastases and skeletal-related events","route":"/terms/bone-metastases/"},{"id":"cancer-health-disparities","kind":"term","name":"Cancer health disparities and equity","route":"/terms/cancer-health-disparities/"},{"id":"rejuv-second-choices-made-at-treatment","kind":"term","name":"Choices made at the time of treatment that change the second cancer risk","route":"/terms/rejuv-second-choices-made-at-treatment/"},{"id":"cytogenetics","kind":"term","name":"Cytogenetics and karyotype","route":"/terms/cytogenetics/"},{"id":"crs","kind":"term","name":"Cytokine release syndrome (CRS)","route":"/terms/crs/"},{"id":"fixed-duration","kind":"term","name":"Fixed-duration vs continuous therapy","route":"/terms/fixed-duration/"},{"id":"flow-cytometry","kind":"term","name":"Flow cytometry (immunophenotyping)","route":"/terms/flow-cytometry/"},{"id":"high-risk-myeloma","kind":"term","name":"High-risk cytogenetics (myeloma)","route":"/terms/high-risk-myeloma/"},{"id":"icans","kind":"term","name":"ICANS (neurotoxicity)","route":"/terms/icans/"},{"id":"imid","kind":"term","name":"Immunomodulatory drugs (IMiDs) and CELMoDs","route":"/terms/imid/"},{"id":"induction-therapy","kind":"term","name":"Induction therapy","route":"/terms/induction-therapy/"},{"id":"leukaemia-type","kind":"term","name":"Leukaemia (tissue type)","route":"/terms/leukaemia-type/"},{"id":"maintenance-therapy","kind":"term","name":"Maintenance therapy","route":"/terms/maintenance-therapy/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"},{"id":"mrd-negativity-myeloma","kind":"term","name":"MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶)","route":"/terms/mrd-negativity-myeloma/"},{"id":"mrd-negative-cr","kind":"term","name":"MRD-negative complete remission","route":"/terms/mrd-negative-cr/"},{"id":"obesity-related-cancers","kind":"term","name":"Obesity-related cancers (IARC list of 13)","route":"/terms/obesity-related-cancers/"},{"id":"rejuv-second-platinum-and-parp-inhibitors","kind":"term","name":"Platinum drugs and PARP inhibitors: the newer leukaemia risk","route":"/terms/rejuv-second-platinum-and-parp-inhibitors/"},{"id":"proteasome-inhibitor","kind":"term","name":"Proteasome inhibitor (bortezomib, carfilzomib, ixazomib)","route":"/terms/proteasome-inhibitor/"},{"id":"r-iss","kind":"term","name":"R-ISS / R2-ISS staging","route":"/terms/r-iss/"},{"id":"smoldering-myeloma","kind":"term","name":"Smouldering myeloma / MGUS","route":"/terms/smoldering-myeloma/"},{"id":"umrd","kind":"term","name":"Undetectable MRD (uMRD / MRD-negative)","route":"/terms/umrd/"},{"id":"vrd","kind":"term","name":"VRd and Dara-VRd (myeloma induction regimens)","route":"/terms/vrd/"}],"trial":[{"id":"nct04776330","kind":"trial","name":"a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","route":"/trials/nct04776330/"},{"id":"nct06508983","kind":"trial","name":"A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients","route":"/trials/nct06508983/"},{"id":"nct06049290","kind":"trial","name":"A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma","route":"/trials/nct06049290/"},{"id":"nct07681596","kind":"trial","name":"A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07681596/"},{"id":"nct07579234","kind":"trial","name":"A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07579234/"},{"id":"nct04988555","kind":"trial","name":"A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)","route":"/trials/nct04988555/"},{"id":"nct05908409","kind":"trial","name":"A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies","route":"/trials/nct05908409/"},{"id":"nct04973605","kind":"trial","name":"A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Darat","route":"/trials/nct04973605/"},{"id":"nct06464991","kind":"trial","name":"A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)","route":"/trials/nct06464991/"},{"id":"nct03246529","kind":"trial","name":"A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Pl","route":"/trials/nct03246529/"},{"id":"nct06140524","kind":"trial","name":"A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With H","route":"/trials/nct06140524/"},{"id":"nct05955508","kind":"trial","name":"A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Deve","route":"/trials/nct05955508/"},{"id":"nct06413498","kind":"trial","name":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","route":"/trials/nct06413498/"},{"id":"nct07391657","kind":"trial","name":"A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela","route":"/trials/nct07391657/"},{"id":"nct07258511","kind":"trial","name":"A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07258511/"},{"id":"nct07518186","kind":"trial","name":"A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07518186/"},{"id":"nct07138209","kind":"trial","name":"A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07138209/"},{"id":"nct05455320","kind":"trial","name":"A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi","route":"/trials/nct05455320/"},{"id":"nct06208150","kind":"trial","name":"A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez","route":"/trials/nct06208150/"},{"id":"nct05572515","kind":"trial","name":"A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With","route":"/trials/nct05572515/"},{"id":"nct03539744","kind":"trial","name":"A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) ","route":"/trials/nct03539744/"},{"id":"nct05535244","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multi","route":"/trials/nct05535244/"},{"id":"nct07589634","kind":"trial","name":"A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relaps","route":"/trials/nct07589634/"},{"id":"nct05583617","kind":"trial","name":"A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma","route":"/trials/nct05583617/"},{"id":"nct00229203","kind":"trial","name":"A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma","route":"/trials/nct00229203/"},{"id":"nct06679101","kind":"trial","name":"A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas","route":"/trials/nct06679101/"},{"id":"nct05521802","kind":"trial","name":"A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct05521802/"},{"id":"nct06550895","kind":"trial","name":"A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma","route":"/trials/nct06550895/"},{"id":"nct05299424","kind":"trial","name":"A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct05299424/"},{"id":"nct03314181","kind":"trial","name":"A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor","route":"/trials/nct03314181/"},{"id":"nct05438043","kind":"trial","name":"A Study of Daratumumab","route":"/trials/nct05438043/"},{"id":"nct06577025","kind":"trial","name":"A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind","route":"/trials/nct06577025/"},{"id":"nct07312188","kind":"trial","name":"A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07312188/"},{"id":"nct06980480","kind":"trial","name":"A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma","route":"/trials/nct06980480/"},{"id":"nct06235229","kind":"trial","name":"A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct06235229/"},{"id":"nct07452198","kind":"trial","name":"A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07452198/"},{"id":"nct06083207","kind":"trial","name":"A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct06083207/"},{"id":"nct04133636","kind":"trial","name":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Mul","route":"/trials/nct04133636/"},{"id":"nct07266441","kind":"trial","name":"A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07266441/"},{"id":"nct06232096","kind":"trial","name":"A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.","route":"/trials/nct06232096/"},{"id":"nct02963493","kind":"trial","name":"A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct02963493/"},{"id":"nct03151811","kind":"trial","name":"A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide","route":"/trials/nct03151811/"},{"id":"nct06679829","kind":"trial","name":"A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant","route":"/trials/nct06679829/"},{"id":"nct07116616","kind":"trial","name":"A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07116616/"},{"id":"nct00434161","kind":"trial","name":"A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma","route":"/trials/nct00434161/"},{"id":"nct04414475","kind":"trial","name":"A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refrac","route":"/trials/nct04414475/"},{"id":"nct05552222","kind":"trial","name":"A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal","route":"/trials/nct05552222/"},{"id":"nct04586426","kind":"trial","name":"A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct04586426/"},{"id":"nct07742215","kind":"trial","name":"A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)","route":"/trials/nct07742215/"},{"id":"nct03933735","kind":"trial","name":"A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct03933735/"},{"id":"nct06115135","kind":"trial","name":"A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma","route":"/trials/nct06115135/"},{"id":"nct07095452","kind":"trial","name":"A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lena","route":"/trials/nct07095452/"},{"id":"nct06953960","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma ","route":"/trials/nct06953960/"},{"id":"nct06892522","kind":"trial","name":"A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe","route":"/trials/nct06892522/"},{"id":"nct06669247","kind":"trial","name":"A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Mult","route":"/trials/nct06669247/"},{"id":"nct05827016","kind":"trial","name":"A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly","route":"/trials/nct05827016/"},{"id":"nct07393282","kind":"trial","name":"A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)","route":"/trials/nct07393282/"},{"id":"nct06952478","kind":"trial","name":"A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone","route":"/trials/nct06952478/"},{"id":"quintessential-2","kind":"trial","name":"A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)","route":"/trials/quintessential-2/"},{"id":"nct06045806","kind":"trial","name":"A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alo","route":"/trials/nct06045806/"},{"id":"nct02773030","kind":"trial","name":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple","route":"/trials/nct02773030/"},{"id":"nct03989414","kind":"trial","name":"A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre","route":"/trials/nct03989414/"},{"id":"nct06988488","kind":"trial","name":"A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatama","route":"/trials/nct06988488/"},{"id":"nct07149857","kind":"trial","name":"A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel","route":"/trials/nct07149857/"},{"id":"nct05552976","kind":"trial","name":"A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants W","route":"/trials/nct05552976/"},{"id":"nct05519085","kind":"trial","name":"A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re","route":"/trials/nct05519085/"},{"id":"nct06500884","kind":"trial","name":"A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events","route":"/trials/nct06500884/"},{"id":"nct05372354","kind":"trial","name":"A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed ","route":"/trials/nct05372354/"},{"id":"nct07227311","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult","route":"/trials/nct07227311/"},{"id":"nct07284758","kind":"trial","name":"A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct07284758/"},{"id":"nct07297329","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","route":"/trials/nct07297329/"},{"id":"nct05704049","kind":"trial","name":"A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory","route":"/trials/nct05704049/"},{"id":"nct05714839","kind":"trial","name":"A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme","route":"/trials/nct05714839/"},{"id":"nct05623020","kind":"trial","name":"A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide","route":"/trials/nct05623020/"},{"id":"nct05020236","kind":"trial","name":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","route":"/trials/nct05020236/"},{"id":"nct05730036","kind":"trial","name":"A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re","route":"/trials/nct05730036/"},{"id":"nct07455851","kind":"trial","name":"A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct07455851/"},{"id":"nct05828511","kind":"trial","name":"A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnose","route":"/trials/nct05828511/"},{"id":"nct07523555","kind":"trial","name":"Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies","route":"/trials/nct07523555/"},{"id":"nct00022282","kind":"trial","name":"AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct00022282/"},{"id":"nct06956170","kind":"trial","name":"All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo","route":"/trials/nct06956170/"},{"id":"nct03844048","kind":"trial","name":"An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial","route":"/trials/nct03844048/"},{"id":"nct06668792","kind":"trial","name":"An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct06668792/"},{"id":"nct01102426","kind":"trial","name":"Aplidin - Dexamethasone in Relapsed/Refractory Myeloma","route":"/trials/nct01102426/"},{"id":"aquila","kind":"trial","name":"AQUILA","route":"/trials/aquila/"},{"id":"nct05850234","kind":"trial","name":"AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)","route":"/trials/nct05850234/"},{"id":"nct06106945","kind":"trial","name":"AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma","route":"/trials/nct06106945/"},{"id":"nct04271644","kind":"trial","name":"BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","route":"/trials/nct04271644/"},{"id":"cartitude-1","kind":"trial","name":"CARTITUDE-1","route":"/trials/cartitude-1/"},{"id":"cartitude-4","kind":"trial","name":"CARTITUDE-4","route":"/trials/cartitude-4/"},{"id":"cartitude-5","kind":"trial","name":"CARTITUDE-5","route":"/trials/cartitude-5/"},{"id":"cartitude-6","kind":"trial","name":"CARTITUDE-6","route":"/trials/cartitude-6/"},{"id":"cassiopeia","kind":"trial","name":"CASSIOPEIA","route":"/trials/cassiopeia/"},{"id":"cepheus","kind":"trial","name":"CEPHEUS","route":"/trials/cepheus/"},{"id":"nct07555938","kind":"trial","name":"Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma","route":"/trials/nct07555938/"},{"id":"nct06868654","kind":"trial","name":"China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame","route":"/trials/nct06868654/"},{"id":"nct03915184","kind":"trial","name":"Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)","route":"/trials/nct03915184/"},{"id":"nct00083382","kind":"trial","name":"Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide","route":"/trials/nct00083382/"},{"id":"nct02739594","kind":"trial","name":"Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma","route":"/trials/nct02739594/"},{"id":"determination","kind":"trial","name":"DETERMINATION","route":"/trials/determination/"},{"id":"nct00033332","kind":"trial","name":"Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma","route":"/trials/nct00033332/"},{"id":"drammatic","kind":"trial","name":"DRAMMATIC","route":"/trials/drammatic/"},{"id":"dreamm-7","kind":"trial","name":"DREAMM-7","route":"/trials/dreamm-7/"},{"id":"dreamm-8","kind":"trial","name":"DREAMM-8","route":"/trials/dreamm-8/"},{"id":"nct07567014","kind":"trial","name":"Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS","route":"/trials/nct07567014/"},{"id":"nct01301963","kind":"trial","name":"Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide","route":"/trials/nct01301963/"},{"id":"fumanba-1","kind":"trial","name":"FUMANBA-1","route":"/trials/fumanba-1/"},{"id":"nct06052826","kind":"trial","name":"Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study","route":"/trials/nct06052826/"},{"id":"nct06566547","kind":"trial","name":"GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct06566547/"},{"id":"nxc-201-mm","kind":"trial","name":"HBI0101 (NXC-201) multiple myeloma phase 1","route":"/trials/nxc-201-mm/"},{"id":"nct05594797","kind":"trial","name":"Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM","route":"/trials/nct05594797/"},{"id":"nct06119685","kind":"trial","name":"IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","route":"/trials/nct06119685/"},{"id":"ifm-2009","kind":"trial","name":"IFM 2009","route":"/trials/ifm-2009/"},{"id":"immagine-1","kind":"trial","name":"iMMagine-1","route":"/trials/immagine-1/"},{"id":"imroz","kind":"trial","name":"IMROZ","route":"/trials/imroz/"},{"id":"nct04270409","kind":"trial","name":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","route":"/trials/nct04270409/"},{"id":"istopmm","kind":"trial","name":"iStopMM","route":"/trials/istopmm/"},{"id":"nct06868667","kind":"trial","name":"Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dex","route":"/trials/nct06868667/"},{"id":"karmma-3","kind":"trial","name":"KarMMa-3","route":"/trials/karmma-3/"},{"id":"legend-2","kind":"trial","name":"LEGEND-2","route":"/trials/legend-2/"},{"id":"linker-mm1","kind":"trial","name":"LINKER-MM1","route":"/trials/linker-mm1/"},{"id":"lummicar-1","kind":"trial","name":"LUMMICAR STUDY 1","route":"/trials/lummicar-1/"},{"id":"magnetismm-3","kind":"trial","name":"MagnetisMM-3","route":"/trials/magnetismm-3/"},{"id":"nct06152575","kind":"trial","name":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other","route":"/trials/nct06152575/"},{"id":"maia","kind":"trial","name":"MAIA","route":"/trials/maia/"},{"id":"majestec-1","kind":"trial","name":"MajesTEC-1","route":"/trials/majestec-1/"},{"id":"majestec-3","kind":"trial","name":"MajesTEC-3","route":"/trials/majestec-3/"},{"id":"nct06483100","kind":"trial","name":"Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance","route":"/trials/nct06483100/"},{"id":"nct00103662","kind":"trial","name":"Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients","route":"/trials/nct00103662/"},{"id":"nct06514508","kind":"trial","name":"Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients","route":"/trials/nct06514508/"},{"id":"monumental-1","kind":"trial","name":"MonumenTAL-1","route":"/trials/monumental-1/"},{"id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/"},{"id":"nct04975997","kind":"trial","name":"Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants ","route":"/trials/nct04975997/"},{"id":"nct00376883","kind":"trial","name":"Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month","route":"/trials/nct00376883/"},{"id":"perseus","kind":"trial","name":"PERSEUS","route":"/trials/perseus/"},{"id":"nct07018050","kind":"trial","name":"Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma","route":"/trials/nct07018050/"},{"id":"nct04126200","kind":"trial","name":"Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple","route":"/trials/nct04126200/"},{"id":"nct06484829","kind":"trial","name":"Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct06484829/"},{"id":"nct05565807","kind":"trial","name":"Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma","route":"/trials/nct05565807/"},{"id":"nct06087653","kind":"trial","name":"Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)","route":"/trials/nct06087653/"},{"id":"nct04977024","kind":"trial","name":"SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer","route":"/trials/nct04977024/"},{"id":"nct02343042","kind":"trial","name":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","route":"/trials/nct02343042/"},{"id":"nct03315026","kind":"trial","name":"Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis","route":"/trials/nct03315026/"},{"id":"nct06158841","kind":"trial","name":"Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto","route":"/trials/nct06158841/"},{"id":"nct06297226","kind":"trial","name":"Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct06297226/"},{"id":"nct07764978","kind":"trial","name":"Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT","route":"/trials/nct07764978/"},{"id":"nct02952508","kind":"trial","name":"Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom","route":"/trials/nct02952508/"},{"id":"nct05862012","kind":"trial","name":"Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)","route":"/trials/nct05862012/"},{"id":"nct04649060","kind":"trial","name":"Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma","route":"/trials/nct04649060/"},{"id":"nct06616389","kind":"trial","name":"Study of ODX (OsteoDex) in Multiple Myeloma","route":"/trials/nct06616389/"},{"id":"nct04782687","kind":"trial","name":"Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma","route":"/trials/nct04782687/"},{"id":"nct04162210","kind":"trial","name":"Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple","route":"/trials/nct04162210/"},{"id":"nct02899052","kind":"trial","name":"Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)","route":"/trials/nct02899052/"},{"id":"nct04879043","kind":"trial","name":"Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma","route":"/trials/nct04879043/"},{"id":"nct04068597","kind":"trial","name":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies","route":"/trials/nct04068597/"},{"id":"nct05317416","kind":"trial","name":"Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant","route":"/trials/nct05317416/"},{"id":"nct07150104","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi","route":"/trials/nct07150104/"},{"id":"nct07217119","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM","route":"/trials/nct07217119/"},{"id":"nct07217184","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM","route":"/trials/nct07217184/"},{"id":"nct07084896","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM","route":"/trials/nct07084896/"},{"id":"nct07150091","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM","route":"/trials/nct07150091/"},{"id":"nct07454187","kind":"trial","name":"To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct07454187/"}],"person":[{"id":"keith-stewart","kind":"person","name":"A. Keith Stewart","route":"/people/keith-stewart/"},{"id":"aaron-ciechanover","kind":"person","name":"Aaron Ciechanover","route":"/people/aaron-ciechanover/"},{"id":"ajai-chari","kind":"person","name":"Ajai Chari","route":"/people/ajai-chari/"},{"id":"akifumi-takaori","kind":"person","name":"Akifumi Takaori","route":"/people/akifumi-takaori/"},{"id":"benjamin-ebert","kind":"person","name":"Benjamin L. Ebert","route":"/people/benjamin-ebert/"},{"id":"ola-landgren","kind":"person","name":"C. Ola Landgren","route":"/people/ola-landgren/"},{"id":"graham-jackson","kind":"person","name":"Graham H. Jackson","route":"/people/graham-jackson/"},{"id":"jesus-berdeja","kind":"person","name":"Jesús G. Berdeja","route":"/people/jesus-berdeja/"},{"id":"jesus-san-miguel","kind":"person","name":"Jesús San Miguel","route":"/people/jesus-san-miguel/"},{"id":"joaquin-martinez-lopez","kind":"person","name":"Joaquín Martínez-López","route":"/people/joaquin-martinez-lopez/"},{"id":"john-dipersio","kind":"person","name":"John F. DiPersio","route":"/people/john-dipersio/"},{"id":"julian-adams","kind":"person","name":"Julian Adams","route":"/people/julian-adams/"},{"id":"jurgen-kuball","kind":"person","name":"Jürgen Kuball","route":"/people/jurgen-kuball/"},{"id":"kenneth-anderson","kind":"person","name":"Kenneth C. Anderson","route":"/people/kenneth-anderson/"},{"id":"maria-victoria-mateos","kind":"person","name":"María-Victoria Mateos","route":"/people/maria-victoria-mateos/"},{"id":"martin-bornhauser","kind":"person","name":"Martin Bornhäuser","route":"/people/martin-bornhauser/"},{"id":"meletios-dimopoulos","kind":"person","name":"Meletios A. Dimopoulos","route":"/people/meletios-dimopoulos/"},{"id":"michel-attal","kind":"person","name":"Michel Attal","route":"/people/michel-attal/"},{"id":"nicolaas-schaap","kind":"person","name":"Nicolaas P.M. Schaap","route":"/people/nicolaas-schaap/"},{"id":"nikhil-munshi","kind":"person","name":"Nikhil C. Munshi","route":"/people/nikhil-munshi/"},{"id":"noopur-raje","kind":"person","name":"Noopur Raje","route":"/people/noopur-raje/"},{"id":"paul-richardson","kind":"person","name":"Paul G. Richardson","route":"/people/paul-richardson/"},{"id":"philippe-moreau","kind":"person","name":"Philippe Moreau","route":"/people/philippe-moreau/"},{"id":"pieter-sonneveld","kind":"person","name":"Pieter Sonneveld","route":"/people/pieter-sonneveld/"},{"id":"polina-stepensky","kind":"person","name":"Polina Stepensky","route":"/people/polina-stepensky/"},{"id":"ralf-c-bargou","kind":"person","name":"Ralf C. Bargou","route":"/people/ralf-c-bargou/"},{"id":"vincent-rajkumar","kind":"person","name":"S. Vincent Rajkumar","route":"/people/vincent-rajkumar/"},{"id":"saad-usmani","kind":"person","name":"Saad Z. Usmani","route":"/people/saad-usmani/"},{"id":"sagar-lonial","kind":"person","name":"Sagar Lonial","route":"/people/sagar-lonial/"},{"id":"shaji-kumar","kind":"person","name":"Shaji K. Kumar","route":"/people/shaji-kumar/"},{"id":"sigurdur-kristinsson","kind":"person","name":"Sigurdur Y. Kristinsson","route":"/people/sigurdur-kristinsson/"},{"id":"stephen-russell","kind":"person","name":"Stephen J. Russell","route":"/people/stephen-russell/"},{"id":"sundar-jagannath","kind":"person","name":"Sundar Jagannath","route":"/people/sundar-jagannath/"},{"id":"thierry-facon","kind":"person","name":"Thierry Facon","route":"/people/thierry-facon/"},{"id":"zelig-eshhar","kind":"person","name":"Zelig Eshhar","route":"/people/zelig-eshhar/"},{"id":"li-zonghai","kind":"person","name":"Zonghai Li","route":"/people/li-zonghai/"}],"journal":[{"id":"blood-cancer-discovery","kind":"journal","name":"Blood cancer discovery","route":"/journals/blood-cancer-discovery/"},{"id":"blood-cancer-journal","kind":"journal","name":"Blood cancer journal","route":"/journals/blood-cancer-journal/"},{"id":"clinical-lymphoma-myeloma-and-leukemia","kind":"journal","name":"Clinical lymphoma, myeloma & leukemia","route":"/journals/clinical-lymphoma-myeloma-and-leukemia/"},{"id":"current-hematologic-malignancy-reports","kind":"journal","name":"Current hematologic malignancy reports","route":"/journals/current-hematologic-malignancy-reports/"},{"id":"haematologica","kind":"journal","name":"Haematologica","route":"/journals/haematologica/"},{"id":"journal-of-hematology-and-oncology","kind":"journal","name":"Journal of hematology & oncology","route":"/journals/journal-of-hematology-and-oncology/"},{"id":"leukemia-and-lymphoma","kind":"journal","name":"Leukemia & lymphoma","route":"/journals/leukemia-and-lymphoma/"}],"idea":[{"id":"idea-moon-neuropathy-prevention-programme","kind":"idea","name":"A prevention programme for chemotherapy nerve damage: SARM1 inhibitors, cooling and compression","route":"/ideas/idea-moon-neuropathy-prevention-programme/"},{"id":"idea-prev-blood-precursor-watch-registry","kind":"idea","name":"A watch-and-wait registry for blood precursor conditions found by chance","route":"/ideas/idea-prev-blood-precursor-watch-registry/"},{"id":"idea-reg-early-apheresis-banking","kind":"idea","name":"Collect and freeze T cells at diagnosis for high-risk patients, before chemotherapy","route":"/ideas/idea-reg-early-apheresis-banking/"},{"id":"idea-tr1-duffy-null-neutrophil-threshold","kind":"idea","name":"Fix the neutrophil count rule that excludes many people of African ancestry","route":"/ideas/idea-tr1-duffy-null-neutrophil-threshold/"},{"id":"idea-reg-hospital-exemption-harmonised","kind":"idea","name":"Harmonise Europe's hospital exemption for academic cell therapies, with one registry","route":"/ideas/idea-reg-hospital-exemption-harmonised/"},{"id":"idea-fund-public-car-t-manufacturing","kind":"idea","name":"Hospital-based CAR-T manufacturing at cost through a public network","route":"/ideas/idea-fund-public-car-t-manufacturing/"},{"id":"idea-reg-point-of-care-cart-network","kind":"idea","name":"Hospital-made CAR-T under one shared regulatory master file","route":"/ideas/idea-reg-point-of-care-cart-network/"},{"id":"idea-moon-in-vivo-cart-generic-price","kind":"idea","name":"In vivo CAR-T manufactured and priced like a generic biologic","route":"/ideas/idea-moon-in-vivo-cart-generic-price/"},{"id":"idea-tr1-organ-impairment-pk-before-approval","kind":"idea","name":"Kidney and liver impairment dosing studies completed before approval, not years after","route":"/ideas/idea-tr1-organ-impairment-pk-before-approval/"},{"id":"idea-fund-milestone-venture-philanthropy","kind":"idea","name":"Milestone-based venture philanthropy with royalties recycled into the pipeline","route":"/ideas/idea-fund-milestone-venture-philanthropy/"},{"id":"idea-mrd-guided-stop-myeloma","kind":"idea","name":"MRD-guided treatment-free intervals in myeloma","route":"/ideas/idea-mrd-guided-stop-myeloma/"},{"id":"idea-car-t-replaces-transplant","kind":"idea","name":"One CAR-T infusion instead of autologous transplant","route":"/ideas/idea-car-t-replaces-transplant/"},{"id":"idea-fund-pay-for-cure-annuities","kind":"idea","name":"Outcome-based annuity payments for potentially curative one-time therapies","route":"/ideas/idea-fund-pay-for-cure-annuities/"},{"id":"idea-bio1-adaptive-car-antigen-switch","kind":"idea","name":"Plan the second CAR-T target before the first one is lost","route":"/ideas/idea-bio1-adaptive-car-antigen-switch/"},{"id":"idea-acc-rapid-diagnostic-centres-vague-symptoms","kind":"idea","name":"Rapid diagnostic centres for people with vague but worrying symptoms","route":"/ideas/idea-acc-rapid-diagnostic-centres-vague-symptoms/"},{"id":"idea-tr1-response-adapted-dose-reduction","kind":"idea","name":"Reduce the dose once the cancer responds: response-adapted de-escalation trials","route":"/ideas/idea-tr1-response-adapted-dose-reduction/"},{"id":"idea-tr1-pk-informed-organ-thresholds","kind":"idea","name":"Replace fixed kidney and liver cut-offs with drug-specific, pharmacology-based thresholds","route":"/ideas/idea-tr1-pk-informed-organ-thresholds/"}],"cancer":[{"id":"myeloma-transplant-eligible","kind":"cancer","name":"Newly diagnosed multiple myeloma, transplant-eligible","route":"/cancers/myeloma-transplant-eligible/"},{"id":"myeloma-transplant-ineligible","kind":"cancer","name":"Newly diagnosed multiple myeloma, transplant-ineligible","route":"/cancers/myeloma-transplant-ineligible/"},{"id":"plasma-cell-leukaemia","kind":"cancer","name":"Plasma cell leukaemia","route":"/cancers/plasma-cell-leukaemia/"},{"id":"plasmablastic-lymphoma","kind":"cancer","name":"Plasmablastic lymphoma","route":"/cancers/plasmablastic-lymphoma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"},{"id":"smouldering-myeloma","kind":"cancer","name":"Smouldering multiple myeloma","route":"/cancers/smouldering-myeloma/"}],"pathway":[{"id":"bcr-signalling","kind":"pathway","name":"B-cell receptor / BTK signalling (to NF-κB)","route":"/pathways/bcr-signalling/"},{"id":"complement-in-cancer","kind":"pathway","name":"Complement in cancer","route":"/pathways/complement-in-cancer/"},{"id":"ubiquitin-proteasome-system","kind":"pathway","name":"Ubiquitin-proteasome system & protein homeostasis","route":"/pathways/ubiquitin-proteasome-system/"}],"bottleneck":[{"id":"b-dormancy-mrd","kind":"bottleneck","name":"Dormant cells and minimal residual disease","route":"/bottlenecks/b-dormancy-mrd/"},{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/"},{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"},{"id":"b-aging-comorbidity","kind":"bottleneck","name":"Older and multimorbid patients are excluded and undertreated","route":"/bottlenecks/b-aging-comorbidity/"},{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/"},{"id":"b-trial-diversity","kind":"bottleneck","name":"Trials do not represent the people who get cancer","route":"/bottlenecks/b-trial-diversity/"}],"paper":[{"id":"paper-cartitude-1-cilta-cel-lancet-2021","kind":"paper","name":"CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma","route":"/key-papers/paper-cartitude-1-cilta-cel-lancet-2021/"},{"id":"paper-cartitude-4-cilta-cel-nejm-2023","kind":"paper","name":"CARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy","route":"/key-papers/paper-cartitude-4-cilta-cel-nejm-2023/"},{"id":"paper-cepheus-dara-vrd-natmed-2025","kind":"paper","name":"CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint","route":"/key-papers/paper-cepheus-dara-vrd-natmed-2025/"},{"id":"paper-nxc-201-hbi0101-asherie-haematologica-2023","kind":"paper","name":"Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial (HBI0101)","route":"/key-papers/paper-nxc-201-hbi0101-asherie-haematologica-2023/"},{"id":"paper-body-fatness-iarc-nejm-2016","kind":"paper","name":"IARC verdict: excess body fat causes 13 cancers","route":"/key-papers/paper-body-fatness-iarc-nejm-2016/"},{"id":"paper-karmma-3-ide-cel-nejm-2023","kind":"paper","name":"KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma","route":"/key-papers/paper-karmma-3-ide-cel-nejm-2023/"},{"id":"paper-magnetismm-3-elranatamab-natmed-2023","kind":"paper","name":"MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response","route":"/key-papers/paper-magnetismm-3-elranatamab-natmed-2023/"},{"id":"paper-maia-daratumumab-rd-nejm-2019","kind":"paper","name":"MAIA: adding daratumumab to lenalidomide-dexamethasone for older patients with newly diagnosed myeloma who cannot have a transplant","route":"/key-papers/paper-maia-daratumumab-rd-nejm-2019/"},{"id":"paper-majestec-1-teclistamab-nejm-2022","kind":"paper","name":"MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma","route":"/key-papers/paper-majestec-1-teclistamab-nejm-2022/"},{"id":"paper-nhs-galleri-performance-nat-med-2026","kind":"paper","name":"Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial","route":"/key-papers/paper-nhs-galleri-performance-nat-med-2026/"},{"id":"paper-perseus-dara-vrd-transplant-nejm-2024","kind":"paper","name":"PERSEUS: daratumumab added to bortezomib-lenalidomide-dexamethasone around autologous transplant in newly diagnosed myeloma","route":"/key-papers/paper-perseus-dara-vrd-transplant-nejm-2024/"},{"id":"paper-russell-mv-nis-myeloma-mayo-2014","kind":"paper","name":"Russell 2014: a measles virus given into the vein put one patient's myeloma into complete remission","route":"/key-papers/paper-russell-mv-nis-myeloma-mayo-2014/"}],"biomarker":[{"id":"bcma-expression","kind":"biomarker","name":"BCMA expression","route":"/biomarkers/bcma-expression/"},{"id":"cd38-expression","kind":"biomarker","name":"CD38 expression","route":"/biomarkers/cd38-expression/"},{"id":"fcrh5-expression","kind":"biomarker","name":"FcRH5 expression","route":"/biomarkers/fcrh5-expression/"},{"id":"gprc5d-expression","kind":"biomarker","name":"GPRC5D expression","route":"/biomarkers/gprc5d-expression/"}]}}